Canopy Growth Crecimiento futuro
Future controles de criterios 1/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Canopy Growth de 49.2% y 10.5% respectivamente, mientras que el BPA crecerá en un 72.7% al año.
Información clave
49.2%
Tasa de crecimiento de los beneficios
72.66%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Pharmaceuticals | 14.8% |
| Tasa de crecimiento de los ingresos | 10.5% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Good |
| Última actualización | 16 Jun 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Actualización de narrativa • Jun 04
WEED: German Medical Relaunch And New Brand Portfolio Will Drive Upside
Analysts have adjusted their price target for Canopy Growth to CA$4.82, with updated assumptions that include a slightly higher discount rate, modestly different revenue growth expectations, a small change in projected profit margin and a revised future P/E estimate. What's in the News Relaunch of the Tweed brand in the German medical cannabis market, with three initial strains supplied by wholly owned subsidiary MTL Cannabis Corp., targeting physicians and patients familiar with the legacy brand.
Actualización de narrativa • May 13
WEED: Expanded Product Line And Equity Raise Will Drive Future Upside
Analysts have modestly reduced their price target on Canopy Growth to CA$2.38, citing slightly higher assumed discount rates, a somewhat stronger profit margin outlook, and a lower future P/E multiple in their refreshed models. What's in the News Canopy Growth and its medical brand Spectrum Therapeutics expanded their Minor Cannabinoid softgel lineup, adding new 30 and 90 pack formats and more dosing options across the Optimized Spectrum portfolio for both daytime and nighttime use (Key Developments).Actualización de narrativa • Apr 26
WEED: New Brand Launch And Equity Raise Will Support Future Upside
Analysts have trimmed their fair value estimate for Canopy Growth from CA$5.00 to CA$4.82, citing updated assumptions that include a slightly lower revenue growth outlook, a higher profit margin and a reduced future P/E multiple. What's in the News Canopy Growth launched Deelish, a new cannabis brand aimed at everyday consumers, with products positioned at everyday price points and high THC content across both flower and pre-roll formats (Key Developments).Actualización de narrativa • Apr 11
WEED: Everyday Brand Launch And Equity Raise Will Support Future Upside
Analysts have adjusted their CA$ price target on Canopy Growth to reflect updated views on long term revenue growth, profit margin assumptions, and a lower projected future P/E multiple. This has resulted in a slightly different outlook than before.Actualización de narrativa • Mar 28
WEED: Term Loan Refinancing Will Support Medical Expansion And New Formats
Analysts have reduced their Canopy Growth fair value estimate from CA$3.20 to about CA$2.38, citing updated assumptions around revenue growth, profit margins, the discount rate, and a lower expected future P/E multiple. What's in the News Canopy Growth filed a follow-on equity offering of approximately $19.27 million, covering 18,705,578 common shares priced at $1.03 each (Key Developments).Actualización de narrativa • Mar 13
WEED: Term Loan And Equity Raise Will Support Future Acquisitions
Analysts have trimmed their CA$ price target on Canopy Growth, citing slightly higher projected revenue growth, a lower profit margin outlook, and a higher assumed future P/E multiple. Together, these factors imply a more cautious stance on the shares.Actualización de narrativa • Feb 26
WEED: Term Loan And Equity Raise Will Support Future Portfolio Expansion
Analysts have adjusted their price target on Canopy Growth to CA$5.00, reflecting updated assumptions for revenue growth, profit margins, and a slightly lower future P/E multiple. What's in the News Filed a follow-on equity offering of approximately $19.27 million, covering 18,705,578 common shares priced at about $1.03 per share (Key Developments).Actualización de narrativa • Feb 11
WEED: Term Loan Funding Will Support Expansion Of Medical And Adult-Use Portfolio
Analysts have trimmed their fair value estimate for Canopy Growth from $8.00 to $5.00, citing higher assumed revenue growth of 14.73% paired with much thinner profit margins of 4.78% and a very large 137.82x future P/E, which together point to a riskier and more expensive earnings profile. What's in the News Canopy Growth entered a term loan agreement to receive net proceeds of US$150 million from lenders led by JGB Management Inc., with the loan maturing in January 2031.Actualización de narrativa • Jan 27
WEED: Medical Expansion And New Product Formats Will Drive Future Upside
Analysts have trimmed their fair value estimate for Canopy Growth from US$3.76 to about US$3.20. This reflects updated assumptions around slower revenue growth, a slightly lower future P/E, and a broadly unchanged margin and discount rate profile.Artículo de análisis • Jan 11
More Unpleasant Surprises Could Be In Store For Canopy Growth Corporation's (TSE:WEED) Shares After Tumbling 28%
Canopy Growth Corporation ( TSE:WEED ) shares have had a horrible month, losing 28% after a relatively good period...Actualización de narrativa • Jan 11
WEED: Medical And Adult Use Product Expansion Will Drive Future Upside
Analysts have made only very small tweaks to their inputs for Canopy Growth, keeping the fair value estimate steady at $3.76 while slightly adjusting assumptions for discount rate, revenue growth, profit margin, and future P/E. Together, these changes support a largely unchanged price target outlook.Actualización de narrativa • Dec 23
WEED: Medical Expansion Will Drive Future Upside For Shares
Analysts have nudged their price target on Canopy Growth higher to reflect an improved fair value estimate, rising from approximately $3.30 to $3.76. This revision is supported by slightly stronger projected revenue growth, a notable uplift in expected profit margins, and a lower anticipated future price to earnings multiple.Actualización de narrativa • Dec 08
WEED: Medical Expansion And Share Consolidation Will Drive Future Upside
Analysts have modestly adjusted their price target on Canopy Growth, citing largely unchanged assumptions for fair value at approximately 3.30 dollars, a stable discount rate near 6.12 percent, and essentially flat outlooks for revenue growth, profit margins, and future valuation multiples. What's in the News Launched Claybourne Gassers All in One vapes featuring high potency liquid diamonds and anti clog, anti burn technology, along with new Claybourne Frosted Flyers infused pre roll variety packs in select Canadian regions and online medical channels (Key Developments) Expanded the Spectrum Therapeutics portfolio in Australia with new CBD, THC, and balanced softgel capsules, deepening the company’s presence in the maturing Australian medical cannabis market (Key Developments) Shareholders approved amendments to the company’s articles to allow a potential consolidation of common and exchangeable shares, giving the board discretionary authority to implement a reverse split within 12 months (Key Developments) Transitioned the DOJA facility in Kelowna, British Columbia, into an exclusive medical cultivation site under a micro cultivation license, focused on small batch craft cannabis for Spectrum Therapeutics patients, including veterans (Key Developments) Appointed Tom Stewart as permanent Chief Financial Officer, formalizing his role after serving as interim CFO and leading efforts to stabilize the balance sheet, cut expenses, and improve liquidity (Key Developments) Valuation Changes Fair Value: Unchanged at approximately CA$3.30 per share, indicating no material revision to intrinsic value estimates.Actualización de narrativa • Nov 24
WEED: Improving Profit Margins And Share Consolidation Will Drive Future Upside
Analysts have raised their price target for Canopy Growth from $1.30 to $3.30. They cite improvements in profit margin projections and expectations of sustained profitability, despite moderated revenue growth forecasts.Artículo de análisis • Nov 15
Canopy Growth Corporation's (TSE:WEED) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Canopy Growth Corporation ( TSE:WEED ) shares have had a horrible month, losing 26% after a relatively good period...Artículo de análisis • Nov 10
Canopy Growth Corporation (TSE:WEED) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Last week, you might have seen that Canopy Growth Corporation ( TSE:WEED ) released its second-quarter result to the...Actualización de narrativa • Nov 10
WEED: Rising Discount Rate Will Pressure Share Price In The Months Ahead
Analysts have adjusted their price target for Canopy Growth downward from $2.64 to $1.30. They cited an increased discount rate as well as ongoing evaluations of profit margin and future earnings potential.Artículo de análisis • Aug 30
Revenues Tell The Story For Canopy Growth Corporation (TSE:WEED) As Its Stock Soars 70%
Canopy Growth Corporation ( TSE:WEED ) shares have had a really impressive month, gaining 70% after a shaky period...Actualización de narrativa • Aug 07
European Expansion And Operational Improvements Will Unlock Cannabis Potential
Consensus analyst price targets for Canopy Growth have been revised lower primarily due to a marked slowdown in forecast revenue growth, resulting in a fair value decrease from CA$3.31 to CA$2.98. What's in the News Canopy Growth introduced its Canadian-grown 7ACRES brand in Australia, expanding its medical cannabis portfolio with high-THC sativa strains Ultra Jack and Jack Frost.Artículo de análisis • May 18
Investors Appear Satisfied With Canopy Growth Corporation's (TSE:WEED) Prospects As Shares Rocket 40%
Those holding Canopy Growth Corporation ( TSE:WEED ) shares would be relieved that the share price has rebounded 40% in...Artículo de análisis • Apr 02
What You Can Learn From Canopy Growth Corporation's (TSE:WEED) P/S After Its 28% Share Price Crash
Unfortunately for some shareholders, the Canopy Growth Corporation ( TSE:WEED ) share price has dived 28% in the last...
Nueva narrativa • Mar 31
New Medical Cannabis And Vaporizer Offerings Will Expand Global Markets
Growth in the medical cannabis sector and product innovation in adult-use and premium vaporizers position Canopy for revenue and market share expansion.Artículo de análisis • Feb 12
Canopy Growth Corporation's (TSE:WEED) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Unfortunately for some shareholders, the Canopy Growth Corporation ( TSE:WEED ) share price has dived 26% in the last...Artículo de análisis • Dec 22
Canopy Growth Corporation's (TSE:WEED) Popularity With Investors Under Threat As Stock Sinks 26%
Unfortunately for some shareholders, the Canopy Growth Corporation ( TSE:WEED ) share price has dived 26% in the last...Artículo de análisis • Nov 05
Canopy Growth Corporation (TSE:WEED) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected
Canopy Growth Corporation ( TSE:WEED ) shareholders are no doubt pleased to see that the share price has bounced 28% in...Artículo de análisis • Aug 28
More Unpleasant Surprises Could Be In Store For Canopy Growth Corporation's (TSE:WEED) Shares After Tumbling 26%
To the annoyance of some shareholders, Canopy Growth Corporation ( TSE:WEED ) shares are down a considerable 26% in the...Artículo de análisis • Aug 17
We Think Canopy Growth (TSE:WEED) Has A Fair Chunk Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 3/31/2029 | 409 | -30 | 25 | 33 | 2 |
| 3/31/2028 | 375 | -134 | -73 | -67 | 5 |
| 3/31/2027 | 345 | -131 | -43 | -26 | 6 |
| 3/31/2026 | 285 | -263 | -70 | -64 | N/A |
| 12/31/2025 | 278 | -327 | -87 | -79 | N/A |
| 9/30/2025 | 279 | -387 | -96 | -88 | N/A |
| 6/30/2025 | 275 | -516 | -133 | -124 | N/A |
| 3/31/2025 | 269 | -604 | -177 | -166 | N/A |
| 12/31/2024 | 277 | -477 | -163 | -155 | N/A |
| 9/30/2024 | 280 | -586 | -167 | -160 | N/A |
| 6/30/2024 | 287 | -602 | -191 | -185 | N/A |
| 3/31/2024 | 297 | -484 | -286 | -282 | N/A |
| 12/31/2023 | 293 | -999 | -407 | -400 | N/A |
| 9/30/2023 | 299 | -991 | -520 | -511 | N/A |
| 6/30/2023 | 317 | -1,025 | -576 | -566 | N/A |
| 3/31/2023 | 333 | -3,079 | -568 | -558 | N/A |
| 12/31/2022 | 367 | -3,051 | -559 | -544 | N/A |
| 9/30/2022 | 423 | -2,938 | -583 | -568 | N/A |
| 6/30/2022 | 466 | -2,766 | -550 | -521 | N/A |
| 3/31/2022 | 476 | -255 | -594 | -546 | N/A |
| 12/31/2021 | 557 | -428 | -587 | -517 | N/A |
| 9/30/2021 | 569 | -1,223 | -552 | -437 | N/A |
| 6/30/2021 | 572 | -1,244 | -644 | -513 | N/A |
| 3/31/2021 | 547 | -1,745 | -622 | -466 | N/A |
| 12/31/2020 | 506 | -2,348 | -803 | -579 | N/A |
| 9/30/2020 | 477 | -1,535 | -1,033 | -681 | N/A |
| 6/30/2020 | 419 | -1,244 | -1,282 | -733 | N/A |
| 3/31/2020 | 399 | -1,321 | -1,495 | -773 | N/A |
| 12/31/2019 | 385 | -415 | N/A | -802 | N/A |
| 9/30/2019 | 344 | -256 | N/A | -709 | N/A |
| 6/30/2019 | 291 | -832 | N/A | -626 | N/A |
| 3/31/2019 | 226 | -736 | N/A | -535 | N/A |
| 12/31/2018 | 155 | -398 | N/A | -332 | N/A |
| 9/30/2018 | 94 | -464 | N/A | -257 | N/A |
| 6/30/2018 | 88 | -148 | N/A | -137 | N/A |
| 3/31/2018 | 78 | -67 | N/A | -82 | N/A |
| 12/31/2017 | 70 | -21 | N/A | -60 | N/A |
| 9/30/2017 | 58 | -19 | N/A | -41 | N/A |
| 6/30/2017 | 49 | -13 | N/A | -36 | N/A |
| 3/31/2017 | 40 | -8 | N/A | -27 | N/A |
| 12/31/2016 | 30 | -1 | N/A | -14 | N/A |
| 9/30/2016 | 24 | -7 | N/A | -15 | N/A |
| 6/30/2016 | 18 | -8 | N/A | -14 | N/A |
| 3/31/2016 | 13 | -3 | N/A | -14 | N/A |
| 12/31/2015 | 8 | 0 | N/A | -14 | N/A |
| 9/30/2015 | 6 | 1 | N/A | -12 | N/A |
| 6/30/2015 | 3 | -5 | N/A | -10 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que WEED siga sin ser rentable en los próximos 3 años.
Beneficios vs. Mercado: Se prevé que WEED siga sin ser rentable en los próximos 3 años.
Beneficios de alto crecimiento: Se prevé que WEED siga sin ser rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (10.5% al año) de WEED crezcan más rápidamente que los del mercado Canadian (4.9% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 10.5% al año) de WEED crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de WEED se prevé que sea elevada dentro de 3 años.
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/06/17 13:36 |
| Precio de las acciones al final del día | 2026/06/17 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2026/03/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Canopy Growth Corporation está cubierta por 20 analistas. 6 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Aaron Grey | Alliance Global Partners |
| Frederico Yokota Choucair Gomes | ATB Cormark |
| Jesse Pytlak | ATB Cormark Historical (Cormark Securities) |